person · Reporting owner

Ratcliffe Liam

Disclosed activity across 12 companies

Tapewire entity: 24504
SEC CIK: 0001547100

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARVINAS, INC.ARVN · Entity 5355	Director	June 16, 2022	June 22, 2022
Aptinyx Inc.APTX · Entity 120922	Director	March 29, 2019	April 02, 2019
Climb Bio, Inc.ELYM · Entity 5064	Director	June 26, 2024	June 28, 2024
Cogent Biosciences, Inc.UMRX · Entity 3793	Director	June 14, 2019	June 18, 2019
Deciphera Pharmaceuticals, Inc.DCPH · Entity 90033	Director · 10% owner	May 17, 2018	May 21, 2018
Disc Medicine, Inc.IRON · Entity 2273	Director	June 18, 2026	June 23, 2026
Iterum Therapeutics plcITRM · Entity 72802	10% owner	May 30, 2018	May 31, 2018
OnKure Therapeutics, Inc.OKUR · Entity 6550	Director	August 07, 2026	August 11, 2026
Passage BIO, Inc.PASG · Entity 7829	Director	May 27, 2021	May 28, 2021
Upstream Bio, Inc.UPB · Entity 5743	Director	June 09, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARVINAS, INC.

Report date June 16, 2022 · Filed June 22, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.79 · Expires 2032-06-15	Direct	10,192	Reported balance After 2022-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-16 · Grant · Acquired 10,192 · Balance 10,192 F1: This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders.

Aptinyx Inc.

Report date March 29, 2019 · Filed April 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2029-03-28	Direct	4,123	Reported balance After 2019-03-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-03-29 · Grant · Acquired 4,123 · Balance 4,123 F1: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2: This option is fully vested at time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

F2: This option is fully vested at time of grant.

Climb Bio, Inc.

Report date June 26, 2024 · Filed June 28, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.89 · Expires 2034-06-25	Direct	10,000	Reported balance After 2024-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-26 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

Cogent Biosciences, Inc.

Report date June 14, 2019 · Filed June 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2029-06-14	Direct	7,881	Reported balance After 2019-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-14 · Grant · Acquired 7,881 · Balance 7,881 F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2: This option is fully vested at time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

F2: This option is fully vested at time of grant.

Deciphera Pharmaceuticals, Inc.

Report date May 17, 2018 · Filed May 21, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.73 · Expires 2028-05-16	Direct	12,000	Reported balance After 2018-05-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-05-17 · Grant · Acquired 12,000 · Balance 12,000 F1: This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan and will vest in full on May 17, 2019, subject to the Reporting Person's continuous service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan and will vest in full on May 17, 2019, subject to the Reporting Person's continuous service with the Issuer.

Disc Medicine, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17	Direct	6,212	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 6,212 · Balance 6,212 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Iterum Therapeutics plc

Report date May 30, 2018 · Filed May 31, 2018

Jointly reported with Lathi Vijay K

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy New Leaf Ventures III, L.P.	1,071,688	Last balance in matching sequence After 2018-05-30 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2018-05-30 · Conversion · Acquired 466,793 · Balance 466,793 F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any. Row 2 · 2018-05-30 · Conversion · Acquired 178,230 · Balance 645,023 F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any. Row 3 · 2018-05-30 · Conversion · Acquired 148,603 · Balance 793,626 F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any. Row 4 · 2018-05-30 · Purchase · Acquired 278,062 · Balance 1,071,688 F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.
Ordinary SharesSEC Table I · non-derivative	IndirectBy New Leaf Biopharma Opportunities II, L.P.	384,615	Reported balance After 2018-05-30 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2018-05-30 · Purchase · Acquired 384,615 · Balance 384,615 F5: These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors are the managing directors of NBPO-IIM and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors, NBPO-IIA and NBPO-IIM each disclaim Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of their respective pecuniary interest therein, if any.
Series A Preferred SharesSEC Table II · derivative / convertible security	IndirectBy New Leaf Ventures III, L.P.	0	Reported balance After 2018-05-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-05-30 · Conversion · Disposed 466,793 · Balance 0 F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F6: Not applicable. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.
Series B-1 Preferred SharesSEC Table II · derivative / convertible security	IndirectBy New Leaf Ventures III, L.P.	0	Reported balance After 2018-05-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-05-30 · Conversion · Disposed 178,230 · Balance 0 F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F6: Not applicable. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.
Series B-2 Preferred SharesSEC Table II · derivative / convertible security	IndirectBy New Leaf Ventures III, L.P.	0	Reported balance After 2018-05-30 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-05-30 · Conversion · Disposed 148,603 · Balance 0 F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration. F6: Not applicable. F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration.

F2: These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the "Managing Directors") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any.

F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration.

F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration.

F5: These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors are the managing directors of NBPO-IIM and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The Managing Directors, NBPO-IIA and NBPO-IIM each disclaim Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of their respective pecuniary interest therein, if any.

F6: Not applicable.

OnKure Therapeutics, Inc.

Report date August 07, 2026 · Filed August 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2036-08-06	Direct	22,350	Reported balance After 2026-08-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-07 · Grant · Acquired 22,350 · Balance 22,350 F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Passage BIO, Inc.

Report date May 27, 2021 · Filed May 28, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2031-05-26	Direct	16,918	Reported balance After 2021-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-05-27 · Grant · Acquired 16,918 · Balance 16,918 F1: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Upstream Bio, Inc.

Report date June 09, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.69 · Expires 2036-06-08	Direct	17,096	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 17,096 · Balance 17,096 F1: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PDS Biotechnology Corp

Report date March 15, 2019 · Filed March 18, 2019

Section 16 reporting ended · disclosed 2019-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,000	Reported balance After 2019-03-15 transaction · row 1 1 source row Row 1 · 2019-03-15 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-03-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-03-15 · Exercise / conversion · Disposed 10,000 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F5: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F6: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,172,434	Reported balance Holding disclosure · report date 2019-03-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,172,434 F2: New Leaf Growth Fund I, L.P. ("NLG I") is the direct beneficial owner of the securities reported. New Leaf Growth Associates I, L.P. ("NLG Growth Associates") is the sole general partner of NLG I. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLG Growth Associates. New Leaf Venture Partners, L.L.C. (the "Management Company") is the Management Company of NLG I. Philippe Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the Managers of NLV Management III. These individuals and Craig L. Slutzkin are officers of the Management Company. The Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NLG I in which such Reporting Person has no pecuniary interest. Cancel
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,172,434	Reported balance Holding disclosure · report date 2019-03-15 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,172,434 F3: New Leaf Ventures III, L.P. ("NLV III") is the direct beneficial owner of the securities reported. New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (the "Management Company") is the Management Company of NLV III. Philippe Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the Managers of NLV Management III. These individuals and Craig L. Slutzkin are officers of the Management Company. The Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NLV III in which such Reporting Person has no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: New Leaf Growth Fund I, L.P. ("NLG I") is the direct beneficial owner of the securities reported. New Leaf Growth Associates I, L.P. ("NLG Growth Associates") is the sole general partner of NLG I. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLG Growth Associates. New Leaf Venture Partners, L.L.C. (the "Management Company") is the Management Company of NLG I. Philippe Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the Managers of NLV Management III. These individuals and Craig L. Slutzkin are officers of the Management Company. The Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NLG I in which such Reporting Person has no pecuniary interest. Cancel

F3: New Leaf Ventures III, L.P. ("NLV III") is the direct beneficial owner of the securities reported. New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. (the "Management Company") is the Management Company of NLV III. Philippe Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the Managers of NLV Management III. These individuals and Craig L. Slutzkin are officers of the Management Company. The Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NLV III in which such Reporting Person has no pecuniary interest.

F4: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F5: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F6: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

iRhythm Holdings, Inc.

Report date October 25, 2016 · Filed October 25, 2016

Jointly reported with New Leaf Ventures II, L.P., Delagardelle Jeani, HUNT RONALD, New Leaf Venture Associates II, L.P., New Leaf Venture Management II, L.L.C., Chambon Philippe O.

Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,741,589	Last balance in matching sequence After 2016-10-25 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2016-10-25 · Conversion · Acquired 1,716,589 · Balance 1,716,589 F1: The Series C Convertible Preferred Stock converted into Common Stock on a 2.24685484-for-1 basis and had no expiration date. F2: The Series D Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F3: The Series E Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest. Row 2 · 2016-10-25 · Purchase · Acquired 25,000 · Balance 1,741,589 F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Conversion · Disposed 610,136 · Balance 0 F1: The Series C Convertible Preferred Stock converted into Common Stock on a 2.24685484-for-1 basis and had no expiration date. F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-10-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-25 · Conversion · Disposed 190,154 · Balance 0 F2: The Series D Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.
Series E Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2016-10-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-10-25 · Conversion · Disposed 155,548 · Balance 0 F3: The Series E Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.
Series D Preferred Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-11-01	Direct	0	Reported balance After 2016-10-25 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-10-25 · Conversion · Disposed 72,389 · Balance 0 F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016. F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Convertible Preferred Stock converted into Common Stock on a 2.24685484-for-1 basis and had no expiration date.

F2: The Series D Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.

F3: The Series E Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.

F4: Reflects 5.882698 for 1 reverse stock split which became effective on October 5, 2016.

F5: Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates II") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management II") is the general partner of NLV Associates II. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi and Liam Ratcliffe are the individual managers of NLV Management II (the "Individual Managers"). NLV Associates II and NLV Management II disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Vijay Lathi is a director of the Issuer and, accordingly, files separate Section 16 reports. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his or her economic interest.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 07, 2026 Filed Aug 11, 2026 20:40 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantStock Option (right to buy) · Derivative	22,350	$0.00 Strike: $4.14	$0.00	Disclosure SEC source: 0001547100-26-000005 · form4-08112026_080842.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,350 Underlying: Class A Common Stock · 22,350 shares Expires 2036-08-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:01 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantStock Option (Right to Buy) · Derivative	6,212	$0.00 Strike: $70.79	$0.00	Disclosure SEC source: 0001193125-26-279734 · ownership.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,212 Underlying: Common Stock · 6,212 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 09, 2026 Filed Jun 12, 2026 00:00 UTC	Upstream Bio, Inc. UPB · Entity 5743	GrantStock Option (Right to Buy) · Derivative	17,096	$0.00 Strike: $6.69	$0.00	Disclosure SEC source: 0001193125-26-268165 · ownership.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,096 Underlying: Common Stock · 17,096 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 04, 2026 Filed Jun 8, 2026 22:27 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantStock Option (right to buy) · Derivative	1,275	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001547100-26-000004 · form4-06082026_100623.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,275 Underlying: Class A Common Stock · 1,275 shares Expires 2036-06-03 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document
March 31, 2026 Filed Apr 1, 2026 21:25 UTC	OnKure Therapeutics, Inc. OKUR · Entity 6550	GrantStock Option (right to buy) · Derivative	15,300	$0.00 Strike: $4.14	$0.00	Disclosure SEC source: 0001547100-26-000003 · form4-04012026_090435.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Class A Common Stock · 15,300 shares Expires 2036-03-30 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on April 30, 2026 and on the last day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 11, 2025 Filed Jun 13, 2025 21:29 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $50.86	$0.00	Disclosure SEC source: 0000950170-25-086393 · ownership.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2026 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:17 UTC	Upstream Bio, Inc. UPB · Entity 5743	GrantStock Option (Right to Buy) · Derivative	17,096	$0.00 Strike: $11.59	$0.00	Disclosure SEC source: 0000950170-25-085370 · ownership.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,096 Underlying: Common Stock · 17,096 shares Expires 2035-06-09 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document
October 10, 2024 Filed Oct 15, 2024 20:15 UTC	Upstream Bio, Inc. UPB · Entity 5743	GrantStock Option (Right to Buy) · Derivative	17,096	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0000950170-24-114681 · ownership.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,096 Underlying: Common Stock · 17,096 shares Expires 2034-10-09 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) October 10, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 26, 2024 Filed Jun 28, 2024 21:09 UTC	Climb Bio, Inc. ELYM · Entity 5064	GrantStock Option (Right To Buy) · Derivative	10,000	$0.00 Strike: $7.89	$0.00	Disclosure SEC source: 0001415889-24-018461 · form4-06282024_090603.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document
June 12, 2024 Filed Jun 14, 2024 20:15 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $38.85	$0.00	Disclosure SEC source: 0000950170-24-073672 · ownership.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2025 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 09, 2023 Filed Jun 9, 2023 22:20 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantStock Option (Right to Buy) · Derivative	7,136	$0.00 Strike: $45.69	$0.00	Disclosure SEC source: 0000899243-23-015267 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,136 Underlying: Common Stock · 7,136 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2024 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document
May 18, 2023 Filed May 22, 2023 21:11 UTC	Climb Bio, Inc. ELYM · Entity 5064	GrantStock Option (Right To Buy) · Derivative	10,000	$0.00 Strike: $3.00	$0.00	Disclosure SEC source: 0001209191-23-031535 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document
December 29, 2022 Filed Jan 3, 2023 22:05 UTC	Disc Medicine, Inc. IRON · Entity 2273	GrantStock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $13.50	$0.00	Disclosure SEC source: 0000899243-23-000301 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-12-28 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
June 16, 2022 Filed Jun 22, 2022 00:00 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	10,192	$0.00 Strike: $36.79	$0.00	Disclosure SEC source: 0001209191-22-038558 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,192 Underlying: Common Stock · 10,192 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document
May 19, 2022 Filed Jun 1, 2022 21:14 UTC	Climb Bio, Inc. ELYM · Entity 5064	GrantStock Option (Right To Buy) · Derivative	10,000	$0.00 Strike: $3.46	$0.00	Disclosure SEC source: 0001209191-22-033220 · doc4.xml · derivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document
December 16, 2021 Filed Dec 17, 2021 02:30 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	37,206	$68.97	$2,566,030.85	Disclosure SEC source: 0000899243-21-048686 · doc4.xml · nonDerivative · entry 8 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 185,686 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.275 to $68.335, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (9). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
December 16, 2021 Filed Dec 17, 2021 02:30 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	48,499	$69.66	$3,378,386.99	Disclosure SEC source: 0000899243-21-048686 · doc4.xml · nonDerivative · entry 7 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 222,892 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.28 to $69.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (8). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
December 15, 2021 Filed Dec 17, 2021 02:30 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	5,695	$65.74	$374,365.95	Disclosure SEC source: 0000899243-21-048686 · doc4.xml · nonDerivative · entry 6 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 271,391 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.92 to $65.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
December 15, 2021 Filed Dec 17, 2021 02:30 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	67,549	$66.50	$4,492,325.98	Disclosure SEC source: 0000899243-21-048686 · doc4.xml · nonDerivative · entry 5 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 277,086 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.93 to $65.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
December 15, 2021 Filed Dec 17, 2021 02:30 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	40,292	$67.46	$2,718,271.58	Disclosure SEC source: 0000899243-21-048686 · doc4.xml · nonDerivative · entry 4 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 344,635 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.94 to $66.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
December 14, 2021 Filed Dec 17, 2021 02:30 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	700	$64.20	$44,941.26	Disclosure SEC source: 0000899243-21-048686 · doc4.xml · nonDerivative · entry 3 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 384,927 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.34 to $64.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
December 14, 2021 Filed Dec 17, 2021 02:30 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	36,308	$65.38	$2,373,958.64	Disclosure SEC source: 0000899243-21-048686 · doc4.xml · nonDerivative · entry 2 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 385,627 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.665 to $64.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
December 14, 2021 Filed Dec 17, 2021 02:30 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	119,456	$66.01	$7,885,099.43	Disclosure SEC source: 0000899243-21-048686 · doc4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 421,935 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.66 to $65.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 15, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	3,532	$83.90	$296,347.16	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 13 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 541,391 F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (14). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 15, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	17,752	$85.07	$1,510,121.81	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 12 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 544,923 F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.57 to $85.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (13). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 12, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	12,760	$84.02	$1,072,100.30	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 11 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 562,675 F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (12). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 12, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	9,660	$84.31	$814,474.21	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 10 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 575,435 F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.14 to $85.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (11). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 12, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	17,449	$85.96	$1,499,886.38	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 9 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 585,095 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.15 to $86.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (10). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 11, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	36,210	$85.92	$3,111,333.39	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 8 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 602,544 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.25 to $86.055, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (9). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 11, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	18,007	$86.38	$1,555,468.07	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 7 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 638,754 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.06 to $87.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (8). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 11, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	5,582	$87.71	$489,591.08	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 6 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 656,761 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.07 to $88.065, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 10, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	199	$86.59	$17,230.63	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 5 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 662,343 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.57 to $86.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 10, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	3,956	$87.11	$344,624.17	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 4 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 662,542 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.65 to $87.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 10, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	5,853	$88.12	$515,759.92	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 3 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 666,498 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.66 to $88.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 10, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	1,498	$89.16	$133,559.88	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 2 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 672,351 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.68 to $89.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 10, 2021 Filed Nov 16, 2021 02:45 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	1,852	$90.18	$167,013.36	Disclosure SEC source: 0000899243-21-044697 · doc4.xml · nonDerivative · entry 1 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 673,849 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.75 to $90.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1). F2 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 09, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	580	$91.33	$52,968.85	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 20 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 675,701 F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.27 to $91.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (19). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 09, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	27,297	$91.85	$2,507,092.97	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 19 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 676,281 F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.37 to $92.365, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (18). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 09, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	5,131	$92.73	$475,799.68	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 18 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 703,578 F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.37 to $93.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (17). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 08, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	3,688	$92.48	$341,051.49	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 17 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 708,709 F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.03 to $92.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (16). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 08, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	11,130	$93.03	$1,035,446.16	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 16 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 712,397 F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.67 to $93.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (15). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 08, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	11,668	$94.20	$1,099,129.10	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 15 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 723,527 F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.71 to $94.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (14). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 08, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	54,568	$94.93	$5,180,254.83	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 14 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 735,195 F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.72 to $95.715, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (13). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	Exercise / conversionStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $33.57	$0.00	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · derivative · entry 22 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2030-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F21 · derivative.exercise_date: This option award was granted on June 3, 2020 and the shares underlying the award vested in full on June 3, 2021. Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	Exercise / conversionStock Option (right to buy) · Derivative	6,423	$0.00 Strike: $22.06	$0.00	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · derivative · entry 21 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,423 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F20 · derivative.exercise_date: This option award was granted on May 23, 2019 and the shares underlying the award vested in full on May 23, 2020. Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	2,747	$89.86	$246,853.66	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 13 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 789,763 F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.51 to $90.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (12). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	8,676	$91.09	$790,300.31	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 12 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 792,510 F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.42 to $91.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (11). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	15,327	$91.81	$1,407,243.91	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 11 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 801,186 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.42 to $92.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (10). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	1,825	$93.03	$169,785.23	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 10 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 816,513 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.52 to $93.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (9). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document
November 05, 2021 Filed Nov 10, 2021 02:47 UTC	ARVINAS, INC. ARVN · Entity 5355	SaleCommon Stock	4,519	$94.08	$425,136.22	Disclosure SEC source: 0000899243-21-043795 · doc4.xml · nonDerivative · entry 9 Ratcliffe Liam · CIK 0001547100 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 818,338 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.75 to $94.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7). F8 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.